In This Issue

• News from the IASLC Tobacco Control Committee

Editorials

• Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?
• Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
• Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?
• Lung Cancer Screening in Never-Smokers

Commentary

• Updates Regarding Biomarker Testing for Non–Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable

Review Articles

• Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
• Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies

Special Article

• Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Original Articles

• Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life: Benefit for Patients With Low Initial Scores (STRIPE Trial)
• Quality of Life in NSCLC Survivors — A Multicenter Cross-Sectional Study
• Role of Low-Dose Computerized Tomography in Lung Cancer Screening among Never-Smokers
• Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study
• A Population-Based Study of Outcomes in Surgically Resected T3N0 Non–Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm
• Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy
• Adjuvant Systemic Therapy in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiation Therapy
• Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma
• Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
• The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
• EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs
• Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects
• Positron-Emission Tomography Scan–Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders

Brief Reports

• Impact of Age on Outcomes with Immunotherapy in Patients with Non–Small Cell Lung Cancer
• Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

Case Report

• Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports